Posted inCardiology news
Evaluating PCSK9 Inhibitor Effects on Outcomes in ASCVD Patients Without Prior Ischemic Events: Real-World Insights
This observational study shows PCSK9 inhibitor monoclonal antibodies significantly reduce ischaemic events and mortality over five years in patients with ASCVD but no prior ischemic events, highlighting their preventive potential in routine clinical practice.